SRR1443955
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1336887 | GTEX | — | 0.952 |
| 2 | SRR1392725 | GTEX | — | 0.951 |
| 3 | SRR1457551 | GTEX | — | 0.943 |
| 4 | SRR1473822 | GTEX | — | 0.943 |
| 5 | SRR1475022 | GTEX | — | 0.936 |
| 6 | SRR1472663 | GTEX | — | 0.934 |
| 7 | SRR1432765 | GTEX | — | 0.920 |
| 8 | SRR1488651 | GTEX | — | 0.919 |
| 9 | SRR1382956 | GTEX | — | 0.910 |
| 10 | SRR1330346 | GTEX | — | 0.908 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.387 | Remibrutinib | — uncovered |
| COAGULATION | 0.313 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.286 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.222 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.209 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.185 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.176 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.171 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.135 | Idelalisib | — uncovered |
| COMPLEMENT | 0.087 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.073 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.053 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.038 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.037 | Inavolisib | — uncovered |
| HYPOXIA | 0.026 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.007 | Inavolisib | — uncovered |